etravirine has been researched along with beta-naphthoflavone in 1 studies
| Studies (etravirine) | Trials (etravirine) | Recent Studies (post-2010) (etravirine) | Studies (beta-naphthoflavone) | Trials (beta-naphthoflavone) | Recent Studies (post-2010) (beta-naphthoflavone) |
|---|---|---|---|---|---|
| 572 | 90 | 321 | 1,238 | 0 | 147 |
| Protein | Taxonomy | etravirine (IC50) | beta-naphthoflavone (IC50) |
|---|---|---|---|
| Cytochrome P450 1A1 | Homo sapiens (human) | 0.054 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.2767 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 2.5149 | |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | 5.4667 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 7.185 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK | 1 |
1 review(s) available for etravirine and beta-naphthoflavone
| Article | Year |
|---|---|
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Topics: Drug Discovery; Hydrogen Bonding; Molecular Structure; Prodrugs; Solubility | 2022 |